First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung CancerBusiness Wire • 06/26/23
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen CriteriaBusiness Wire • 06/16/23
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant LymphomaBusiness Wire • 06/12/23
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 CongressBusiness Wire • 06/10/23
SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological MalignanciesBusiness Wire • 06/08/23
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AMLBusiness Wire • 05/26/23
Innate Pharma Reports First Quarter 2023 Financial Results and Business UpdateBusiness Wire • 05/10/23
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual MeetingBusiness Wire • 05/03/23
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023Business Wire • 04/07/23
Innate Pharma Files Its 2022 Universal Registration Document (Document d'enregistrement universel) and 2022 Annual Report on Form 20-FBusiness Wire • 04/06/23
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research ProgramBusiness Wire • 04/03/23
Innate Pharma Reports Full Year 2022(1) Financial Results and Business UpdateBusiness Wire • 03/23/23
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial ResultsBusiness Wire • 03/16/23
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell EngagersBusiness Wire • 01/25/23
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature BiotechnologyBusiness Wire • 01/16/23